PureTech Health (LON:PRTC) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• The stock passed below its 200-day moving average (GBX 125.99), trading as low as GBX 120 and last at GBX 124.60 on a volume of 907,210 shares.
• PureTech has a market cap of £305.25 million and a P/E of 7.38, but carries high leverage with a debt-to-equity ratio of 5.56 while reporting strong liquidity (current ratio 8.49, quick ratio 2.51).
• The company is a clinical-stage biopharma developing therapies across the nervous, gastrointestinal and immune systems, including a microbiome-immune discovery platform, oral weight-loss/glycaemic candidates, and neurotech/noninvasive neurostimulation products.

PureTech Health plc (LON:PRTC - ) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 125.99 and traded as low as GBX 120. PureTech Health shares last traded at GBX 124.60, with a volume of 907,210 shares traded.

PureTech Health Stock Up 0.6%

The company has a debt-to-equity ratio of 5.56, a quick ratio of 2.51 and a current ratio of 8.49. The firm has a market cap of £305.25 million, a price-to-earnings ratio of 7.38 and a beta of 0.71. The firm has a 50-day moving average price of GBX 121.78 and a two-hundred day moving average price of GBX 125.99.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.